Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results

The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.